These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 12938634)
1. [The role of the peripheral nervous system damage in clinical picture of multiple sclerosis]. Gusev EI; Lashch NIu; Boĭko AN; Demina TL Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):47-52. PubMed ID: 12938634 [TBL] [Abstract][Full Text] [Related]
2. Autoimmune disorders affecting both the central and peripheral nervous system. Kamm C; Zettl UK Autoimmun Rev; 2012 Jan; 11(3):196-202. PubMed ID: 21619947 [TBL] [Abstract][Full Text] [Related]
3. [Chronic inflammatory demyelinating polyradiculoneuropathy associated with central nervous system involvement--as compared to multiple sclerosis]. Komori T; Ohtake T; Miyazaki Y; Hirose K; Tanabe H Rinsho Shinkeigaku; 1990 Sep; 30(9):939-43. PubMed ID: 2265502 [TBL] [Abstract][Full Text] [Related]
4. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Goodin DS; Bates D Mult Scler; 2009 Oct; 15(10):1175-82. PubMed ID: 19737851 [TBL] [Abstract][Full Text] [Related]
5. Peripheral nervous system in multiple sclerosis-understanding the involvement via autonomic nervous system. Adamec I; Krbot Skorić M; Habek M Neurol Sci; 2021 Jul; 42(7):2731-2736. PubMed ID: 34036450 [TBL] [Abstract][Full Text] [Related]
6. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for multiple sclerosis. Tremlett H Neurology; 2002 Jun; 58(12):1868. PubMed ID: 12084903 [No Abstract] [Full Text] [Related]
7. Betaseron: a breakthrough treatment for multiple sclerosis. Morrison W; Nelson J Can Nurse; 1996 Oct; 92(9):38-41. PubMed ID: 9118060 [TBL] [Abstract][Full Text] [Related]
8. Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. Falcone M; Scalise A; Minisci C; Romito D; Cancelli I; Gigli GL Neurol Sci; 2006 Apr; 27(1):58-62. PubMed ID: 16688601 [TBL] [Abstract][Full Text] [Related]
9. [Chronic demyelinating polyneuropathy associated with multiple sclerosis: a patient with two diseases]. Quesada MA; Izquierdo G; Bautista J; Chinchón I Rev Neurol; 1995; 23(123):1053-5. PubMed ID: 8556591 [TBL] [Abstract][Full Text] [Related]
10. [A short history of beta-interferon therapy of multiple sclerosis]. Stock G; Horowski R Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113 [TBL] [Abstract][Full Text] [Related]
11. Role of inflammation and apoptosis in multiple sclerosis: Comparative analysis between the periphery and the central nervous system. Macchi B; Marino-Merlo F; Nocentini U; Pisani V; Cuzzocrea S; Grelli S; Mastino A J Neuroimmunol; 2015 Oct; 287():80-7. PubMed ID: 26439966 [TBL] [Abstract][Full Text] [Related]
12. Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy. Minagar A; Maghzi AH; McGee JC; Alexander JS Neurol Res; 2012 Oct; 34(8):738-45. PubMed ID: 22828184 [TBL] [Abstract][Full Text] [Related]
13. [New approaches in research of therapy of multiple sclerosis]. Hemmer B; Cepok S; Nessler S; Sommer N Med Klin (Munich); 2001 Sep; 96 Suppl 1():23-8. PubMed ID: 11603112 [TBL] [Abstract][Full Text] [Related]
14. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis. Duchini A Am J Gastroenterol; 2002 Mar; 97(3):767-8. PubMed ID: 11922585 [No Abstract] [Full Text] [Related]
15. Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review. Amaria RN; Corboy JR; Finlayson CA; Robinson WA; Borges VF Clin Breast Cancer; 2008 Oct; 8(5):449-52. PubMed ID: 18952560 [TBL] [Abstract][Full Text] [Related]
16. Asymptomatic peripheral retinal hemorrhages as a manifestation of interferon beta 1a retinopathy. Bakri SJ; Swanson JW Semin Ophthalmol; 2015 Jan; 30(1):56-7. PubMed ID: 23952180 [TBL] [Abstract][Full Text] [Related]
17. [Current data on interferon therapy of multiple sclerosis in patients at developmental age]. Smigielska-Kuzia J; Sobaniec W; Kułak W; Boćkowski L; Wołk M; Sołowiej E; Artemowicz B Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S45-51. PubMed ID: 15045867 [TBL] [Abstract][Full Text] [Related]
18. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409 [TBL] [Abstract][Full Text] [Related]
19. Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis. Alanoglu G; Kilbas S; Arslan C; Senol A; Kutluhan S Mult Scler; 2007 Jun; 13(5):683-5. PubMed ID: 17548453 [TBL] [Abstract][Full Text] [Related]